Skip to content

Ropivacaine versus Ropivacaine plus Dexmedetomidine for intraperitoneal instillation and port-site infiltration for pain relief after laparoscopic hysterectomy

A Double Blind Randomized Control Study Comparing Ropivacaine and Ropivacaine plus Dexmedetomidine for intraperitoneal instillation and port-site infiltration for pain relief after laparoscopic hysterectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030820
Enrollment
80
Registered
2021-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Ropivacaine: Intraperitoneal and infiltration on the port-site with 0.5% ropivacaine 2mg/kg diluted with normal saline to 50 ml Control Intervention1: Ropivacaine plus dexmedetomidine

Sponsors

NH Rabindranath Tagore International Institute of Cardiac Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who gave written informed consent 2. ASA Physical Status I, II or III 3. Age 35-60 years 4. Elective laparoscopic hysterectomy under general anaesthesia

Exclusion criteria

Exclusion criteria: Patients who: 1. Refused to sign the consent 2. Had allergic history to any drug 3. Were unable to understand VAS 4. Were drug addicts and psychiatric patients 5. Had genital malignancy 6. Had deep pelvic endometriosis

Design outcomes

Primary

MeasureTime frame
- Comparative pain assessment using VAS score in 2 groups - Time to first rescue analgesia - Total analgesic consumptionTimepoint: 30 min 1 hour 4 hour 8 hour 12 hour 16 hour 24 hours

Secondary

MeasureTime frame
Post op Nause & Vomitting Any other adverse eventTimepoint: 24hour

Countries

India

Contacts

Public ContactKamya Bansal

NH Rabindranath Tagore International Institute of Cardiac Sciences

rajatroy88@gmail.com91-9463954608

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026